Last updated on September 2020

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy


Brief description of study

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Detailed Study Description

Global Phase 3, open label long term extension safety study designed to obtain additional safety data for tafamidis meglumine 20 mg and 80 mg (or tafamidis 61 mg where available), and to continue to provide enrolled subjects with tafamidis for up to 60 months, or until subject has access to tafamidis for ATTR CM via prescription, whichever occurs first.

Clinical Study Identifier: NCT02791230

Find a site near you

Start Over

UAB Hospital

Birmingham, AL United States
  Connect »

California Heart Center

Beverly Hills, CA United States
  Connect »

Cedars-Sinai Heart Institute

Beverly Hills, CA United States
  Connect »

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

UCSF Ambulatory Care Center

San Francisco, CA United States
  Connect »

University of California

San Francisco, CA United States
  Connect »

Sylvester at Deerfield Beach

Deerfield Beach, FL United States
  Connect »

Northwestern Medical Group

Chicago, IL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Johns Hopkins Hospital

Baltimore, MD United States
  Connect »

Boston Medical Center

Boston, MA United States
  Connect »

Mayo Clinic Hospital-Rochester

Rochester, MN United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

NYU Langone Health

New York, NY United States
  Connect »

Duke University

Durham, NC United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Penn Presbyterian Medical Center

Philadelphia, PA United States
  Connect »

University of Utah

Salt Lake City, UT United States
  Connect »

University of Utah Medical Center

Salt Lake City, UT United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Vanderbilt Univ. Med. Ctr

Nashville, TN United States
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Huntsman Cancer Hospital

Salt Lake City, UT United States
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Instituto Cardiovascular de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

John Hopkins University

Baltimore, MD United States
  Connect »

Skellefte Lasarett

Skellefteå, Sweden
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.